A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

NCT00768339 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Slow recruitment

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, B-Cell

Interventions

DRUG: AEG35156 antisense IV infusion

Sponsor

Aegera Therapeutics

Collaborators

[object Object]